Unusual Options Activity Detected in Biotech Giants Regeneron and Biogen

Market data reveals a surge in options trading for two major biotechnology firms, Regeneron Pharmaceuticals (REGN) and Biogen Inc (BIIB), as traders position themselves for potential volatility in the coming weeks. The activity is heavily concentrated in contracts expiring May 15, 2026, suggesting a short-term tactical play by institutional or sophisticated retail traders looking to capitalize on near-term price swings. Regeneron saw 3,177 contracts traded, which represents approximately 47.9% of the company's average daily trading volume of 663,385 shares. The most notable activity occurred at the $795 strike call option, where 1,091 contracts were traded, signaling a bullish outlook for the stock. Conversely, Biogen experienced a volume of 5,898 contracts, representing 43.3% of its monthly average daily volume of 1.4 million shares. The focus for BIIB was decidedly bearish, with 1,509 contracts traded for the $170 strike put option. While unusual options flow is not a guaranteed indicator of future price action, the concentration of calls in REGN and puts in BIIB suggests divergent sentiment between these two healthcare peers as they approach the May expiration date.